Company intelligence / Profile preview
CDG Therapeutics, Inc.
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 2
Overview
CDG Therapeutics has completed two Phase I clinical trials with its lead peptide drug, p28. These studies demonstrated extraordinary safety as well as significant tumor regression and extended survival in patients with refractory adult solid tumors and pediatric CNS cancers. The results suggest potential efficacy across a broad range of advanced cancers while reducing adverse side effects typical of existing therapies[6][4].
- Therapeutic areas
- Oncology
- Modalities
- Cell penetrating peptides (CPPs)Synthetic peptidesPeptide therapeutics
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on CDG Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDG Therapeutics, Inc..